The Pioneer and Novo Nordisk Golden Ticket Programme
Pioneer Group has partnered with global healthcare company Novo Nordisk to launch a Golden Ticket designed to help accelerate innovations in cardiometabolic health and rare blood and rare endocrine disorders.
The Golden Ticket programme is aimed at early-stage biotech companies focused on novel drug targets and transformational medicines, with robust research plans and potential for successful research development.
Are you passionate about making a difference in the fields of:
- Diabetes
- Obesity
- Cardiovascular Disease
- Metabolic Disease Co-morbidities & Rare Disease
- Drug Discovery & Enabling Technology?
Why Apply?
If you’re working on ground-breaking solutions in these critical areas, we want to support you in turning your vision into reality. This is your chance to harness our world-class resources and take your innovation to the next level.